Acumen Pharmaceuticals Inc
(NAS:ABOS)
$
2.91
0.1 (3.56%)
Market Cap: 174.83 Mil
Enterprise Value: -57.43 Mil
PE Ratio: 0
PB Ratio: 0.72
GF Score: 30/100 - Q2 2024 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 13, 2024$2.77 (+8.20%)Earnings
- Q1 2024 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2024$3.69 (+9.82%)Earnings
- Q4 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptMar 26, 2024$3.75 (-11.76%)Earnings
- Acumen Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptNov 13, 2023$2.03 (+6.84%)Earnings
- Acumen Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 09, 2023
- Q2 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2023$7Earnings
- Acumen Pharmaceuticals, Inc. - Special Call TranscriptJul 17, 2023
- Acumen Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2023$5.73 (+18.14%)Earnings
- Q4 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptMar 27, 2023$4.21 (+7.40%)Earnings
- Q2 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 15, 2022$5.41 (+0.19%)Earnings
- Q1 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 16, 2022Earnings
Acumen Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 09, 2023 / 03:00PM GMT
Release Date Price:
$1.86
(-8.82%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst
Good morning, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analysts. My pleasure to have Acumen Pharmaceuticals with us here today. On behalf of the company, we have Dan O'Connell, President and CEO. Dan, thanks for being with us today.
Daniel J. O;Connell
Acumen Pharmaceuticals, Inc. - CEO, President & Director
' -
Thanks, Colin.
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst
So it's great to have you here sort of right after CTAD and some really interesting developments in the overall Alzheimer's space. Obviously, you guys had a presence at CTAD, some interesting updates. Before we sort of dig into 193, just what were some of the sort of most interesting takeaways for the field that you walked away with?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)